Phase II study of avelumab in multiple relapsed/refractory germ cell cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II study of avelumab in multiple relapsed/refractory germ cell cancer
Authors
Keywords
Avelumab, Germ cell tumors, Immune checkpoint inhibitors, PD-L1 expression, Refractory germ cell tumors
Journal
INVESTIGATIONAL NEW DRUGS
Volume 37, Issue 4, Pages 748-754
Publisher
Springer Science and Business Media LLC
Online
2019-06-01
DOI
10.1007/s10637-019-00805-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genomic Features for Therapeutic Insights of Chemotherapy‐Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal Counterpart
- (2019) Andrea Necchi et al. ONCOLOGIST
- Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
- (2019) Ulrich Keilholz et al. Journal for ImmunoTherapy of Cancer
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
- (2018) Manish R Patel et al. LANCET ONCOLOGY
- An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis
- (2018) Andrea Necchi et al. EUROPEAN UROLOGY
- Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation
- (2017) Stefanie Zschäbitz et al. EUROPEAN JOURNAL OF CANCER
- Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors
- (2017) Michal Chovanec et al. Oncotarget
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Phase II study of everolimus in refractory testicular germ cell tumors
- (2016) Michal Mego et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors
- (2015) Z. Cierna et al. ANNALS OF ONCOLOGY
- Frequent PD-L1 expression in testicular germ cell tumors
- (2015) C D Fankhauser et al. BRITISH JOURNAL OF CANCER
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sunitinib in Patients with Cisplatin-Refractory Germ Cell Tumors
- (2012) Maria Reckova et al. ONKOLOGIE
- Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design
- (2011) Darren R. Feldman et al. CANCER
- Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database
- (2011) Anja Lorch et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors
- (2009) Darren R. Feldman et al. INVESTIGATIONAL NEW DRUGS
- Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features
- (2009) Ugo De Giorgi et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More